| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/23/2002 | WO2002040026A1 A new use of a pyridazinone derivative |
| 05/23/2002 | WO2002040025A1 Anti-inflammatory agents |
| 05/23/2002 | WO2002040024A1 Novel uses of combined 5-ht1a agonists and serotonin reuptake inhibitors |
| 05/23/2002 | WO2002040023A1 Novel use |
| 05/23/2002 | WO2002040022A1 Treatment of sexual dysfunction using bombesin antagonist |
| 05/23/2002 | WO2002040021A2 Methods for inhibiting the transmission of hiv using topically applied substituted 6-benzyl-4-oxopyrimidines |
| 05/23/2002 | WO2002040020A1 Novel use of certain insulin sensitizers or ppar-gamma agonists |
| 05/23/2002 | WO2002040018A1 Treatment of glaucoma and ocular hypertension |
| 05/23/2002 | WO2002040017A1 Cancer chemotherapeutical and chemopreventive agent |
| 05/23/2002 | WO2002040016A2 Association of calpain inhibitors and reactive oxygen species trapping agents |
| 05/23/2002 | WO2002040015A1 Protein prenyl transferase inhibitors in the treatment of neuroinflammatory disease |
| 05/23/2002 | WO2002040014A1 Fat composition for oral or enteral administration and hexacosanoic acid depressant |
| 05/23/2002 | WO2002040013A1 Composition for stimulating the immune defence and iron metabolism, containing propionyl l-carnitine and lactoferrin |
| 05/23/2002 | WO2002040012A1 Composition for the prevention and/or treatment of lipid metabolism disorders and allergic forms |
| 05/23/2002 | WO2002040011A1 Process for producing drug granules containing branched amino acids |
| 05/23/2002 | WO2002040010A1 Nateglinide-containing hydrophilic drug preparations |
| 05/23/2002 | WO2002040009A1 Gaba enhancers in the treatment of diseases relating to reduced neurosteroid activity |
| 05/23/2002 | WO2002040008A2 Treatment of sexual dysfunction with non peptide bombesin receptor antagonists |
| 05/23/2002 | WO2002040007A1 Synergistic combinations comprising a renin inhibitor for cardiovascular diseases |
| 05/23/2002 | WO2002040006A2 Treatment of anxiety disorders |
| 05/23/2002 | WO2002040005A2 Blockade of sodium channels by phenol derivatives |
| 05/23/2002 | WO2002040004A1 Pharmaceutical or cosmetic composition and use of a pkc inhibitor with an mmp inhibitor for inhibiting langerhans' cell migration |
| 05/23/2002 | WO2002040003A1 Method for producing an organic solvent-free lycopene concentrate, the resulting concentrate and composition comprising said concentrate |
| 05/23/2002 | WO2002040002A2 Method for modulation, stimulation, and inhibition of glutamate reuptake |
| 05/23/2002 | WO2002040001A2 Compositions for treatment of malignant effusions comprising a biocompatible polymer and antineoplastic taxane |
| 05/23/2002 | WO2002040000A2 Use of cci-779 as an antineoplastic agent |
| 05/23/2002 | WO2002039999A2 Use of suramine, l-histidine, quisqualic acid or d-cycloserine for angiogenesis inhibition |
| 05/23/2002 | WO2002039998A2 Methods and compositions for regulating memory consolidation |
| 05/23/2002 | WO2002039997A2 Ace-2 modulating compounds and use thereof |
| 05/23/2002 | WO2002039996A2 Combined therapy against tumors comprising estramustine phosphate and lhrh agonists or antagonists |
| 05/23/2002 | WO2002039995A2 Combination therapy for estrogen-dependent disorders |
| 05/23/2002 | WO2002039994A2 Methods for the treatment and prevention of urinary stone disease |
| 05/23/2002 | WO2002039991A2 Prevention of development of dyskinesias |
| 05/23/2002 | WO2002039990A2 Method for screening anti-proliferative compounds and inhibiting tumor growth |
| 05/23/2002 | WO2002039989A1 Novel use of combined 5-ht1a agonists and selective serotonin reuptake inhibitors |
| 05/23/2002 | WO2002039988A2 Novel uses of combined selective dopamine d2 receptor antagonists and 5-ht1a receptor agonists |
| 05/23/2002 | WO2002039987A2 Use of malaria parasite anion channel blockers for treating malaria |
| 05/23/2002 | WO2002039984A2 Medicine based on anti-hyperglycaemic microcapsules with prolonged release |
| 05/23/2002 | WO2002039983A2 Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs |
| 05/23/2002 | WO2002039981A1 Microgranules based on active principle and method for making same |
| 05/23/2002 | WO2002039980A2 Capsule of cellulose derivatives such as hpmc containing benzimidazole derivatives such as omeprazole |
| 05/23/2002 | WO2002039978A1 Supplement to be enterally administered for parenteral nutrition or partial enteral/oral nutrition of the critically ill, the chronically ill and people with malnutrition |
| 05/23/2002 | WO2002039977A2 A method for restoring a foot fat-pad |
| 05/23/2002 | WO2002039976A1 Use of 2-oxothiazolidine 4-carboxylic acid derivatives as agents promoting skin peeling |
| 05/23/2002 | WO2002039975A1 Use of at least a sulphonic amino derivative in a composition promoting skin peeling |
| 05/23/2002 | WO2002039963A1 Antifungal nail composition and method of use |
| 05/23/2002 | WO2002039960A2 Cosmetic method of treating skin |
| 05/23/2002 | WO2002039958A2 Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents |
| 05/23/2002 | WO2002039956A2 Black tea extract for prevention of disease |
| 05/23/2002 | WO2002039954A2 Novel compounds |
| 05/23/2002 | WO2002039953A2 Texaphyrin coordination compounds and uses thereof |
| 05/23/2002 | WO2002039885A2 Compositions and methods for the therapy and diagnosis of ovarian cancer |
| 05/23/2002 | WO2002039879A2 Treatment of anti-depression drug-induced sexual dysfunction with apomorphine |
| 05/23/2002 | WO2002039835A1 Indigestible oligosaccharides and magnesium absorption in humans |
| 05/23/2002 | WO2002039834A1 Nutritional composition for an immune condition |
| 05/23/2002 | WO2002034267A8 Combination of a transdermal therapeutic system and an oral and/or parenteral preparation containing dopamine agonists for the treatment of dopaminergic disease states |
| 05/23/2002 | WO2002022612A8 Thiazolidine derivatives and its use as antifungal agent |
| 05/23/2002 | WO2002015903A3 Novel pharmaceutical composition for administering n-0923 |
| 05/23/2002 | WO2002014313A3 Novel beta-amyloid inhibitors, method for producing the same and the use thereof as medicaments |
| 05/23/2002 | WO2002006213A3 Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids |
| 05/23/2002 | WO2002005823A3 USE OF 2-METHYLENE-19-NOR-20(S)-1α,25-DIHYDROXYVITAMIN D3 TO INCREASE BONE STRENGTH |
| 05/23/2002 | WO2002003970A3 Matrix controlled transdermal system for stabile derivatives of ace inhibitors |
| 05/23/2002 | WO2002003915A3 Methods of producing weight loss and treatment of obesity |
| 05/23/2002 | WO2002002116A3 Therapeutic treatment of cancer with a protein kinase c inhibitor |
| 05/23/2002 | WO2002002115A3 Anthelminthic agents for the prevention of parasitic infections in humans and animals |
| 05/23/2002 | WO2002000638A3 Substituted phthalides as anti-convulsive drugs |
| 05/23/2002 | WO2001098235A3 3,4-dihydroxybenzyl-substituted carbonic acid derivatives and the use thereof as antioxidants |
| 05/23/2002 | WO2001097749A3 The use of synthetic, non-hormonal 21-aminosteroids and thereof |
| 05/23/2002 | WO2001093846A3 Method for treating respiratory disorders associated with pulmonary elastic fiber injury comprising the use of clycosaminoglycans |
| 05/23/2002 | WO2001093701A3 Aqueous chondroprotective compositions having defined ph limitations for efficacious delivery |
| 05/23/2002 | WO2001092253A3 Inhibitors of alpha l beta 2 mediated cell adhesion |
| 05/23/2002 | WO2001091796A8 Methods, compounds and compositions for treating gout |
| 05/23/2002 | WO2001091720A3 Preparation of injectable suspensions having improved injectability |
| 05/23/2002 | WO2001089494A3 Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases |
| 05/23/2002 | WO2001087884A3 Polyketide derivatives |
| 05/23/2002 | WO2001087882A3 Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors |
| 05/23/2002 | WO2001087346A3 Dendritic cells loaded with toxic substances |
| 05/23/2002 | WO2001087284A3 Aldosterone antagonist composition for release during aldosterone acrophase |
| 05/23/2002 | WO2001085151A3 Chimeric animal model and treatment of psoriasis |
| 05/23/2002 | WO2001085116A3 Synergistic antiplaque/antigingivitis oral composition |
| 05/23/2002 | WO2001083513A3 Antisense modulation of inhibitor of dna binding-1 expression |
| 05/23/2002 | WO2001083479A3 Process for the preparation of pyrazolopyridine derivatives |
| 05/23/2002 | WO2001082948A3 Uses of tgap7 for the modulation of leucocyte activation |
| 05/23/2002 | WO2001082921A8 Use of d-chiro-inositol in the treatment of conditions associated with hypothalamic gene expression |
| 05/23/2002 | WO2001082895A3 Guaifenesin sustained release formulation and tablets |
| 05/23/2002 | WO2001081577A3 Dna encoding the prost 03 polypeptide |
| 05/23/2002 | WO2001081340A3 Heterocycles that are inhibitors of impdh enzyme |
| 05/23/2002 | WO2001081316A3 Substituted phenyl farnesyltransferase inhibitors |
| 05/23/2002 | WO2001080845A3 (2-aminoethyl) oxime derivatives for the treatment of depression |
| 05/23/2002 | WO2001080839A3 Use of naphthindazole-4,9-quinones as antiparasitic agents |
| 05/23/2002 | WO2001080838A3 Use of n2-substituted benz[f]indazole-4,9-quinones as antiparasitic agents |
| 05/23/2002 | WO2001080828A3 Improved water-insoluble drug particle process |
| 05/23/2002 | WO2001079180A3 5-substituted tetralones as inhibitors of ras farnesyl transferase |
| 05/23/2002 | WO2001079179A3 Dihydro-2h-naphthalene-1-one inhibitors of ras farnesyl transferase |
| 05/23/2002 | WO2001079164A3 N-substituted dithiocarbamates for the treatment of biological disorders |
| 05/23/2002 | WO2001078692A3 Membrane delivery system |
| 05/23/2002 | WO2001078660A3 Topical micronutrient delivery system and uses thereof |
| 05/23/2002 | WO2001076637A3 Peptide conjugates for drug delivery |
| 05/23/2002 | WO2001074394A8 New combination of a betablocker and a cholesterol-lowering agent |
| 05/23/2002 | WO2001074348A8 Vasopeptidase inhibitors to treat isolated systolic hypertension |